Back To Search Results

Powassan Virus

Editor: Rebecca Zash Updated: 3/27/2023 8:31:11 PM

Introduction

Powassan virus (POW) is an arbovirus within the family of Flaviviruses primarily found in the Northeastern United States, Canada, and Russia.[1][2][3] It is a zoonotic infection transmitted to humans by several tick species and is the only member of the tick-borne flaviviruses endemic to North America.[4] It was first recognized as a human pathogen in 1958 in Powassan, Ontario. Researchers recovered the virus on autopsy from the brain tissue of a child who died from encephalitis.[5] 

Neurologic manifestations represent the most severe POW virus infection presentation, and the majority of cases that present requiring medical care are characterized by encephalitis or meningoencephalitis. In neurologic involvement cases, the case fatality rate is estimated to be between 10% to 15%.[6][7] Although neuroinvasive infections remain, relatively rare cases have been increasing across the US and Canada over the past decade. The steady increase in cases is likely due both to increased arboviral testing and surveillance and disease emergence.[8][9] 

Evaluation for POW virus infection should be undertaken in those who present with geographic risk factors and a syndrome consistent with encephalitis or meningoencephalitis.

Etiology

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Etiology

Taxonomically POW virus is an arbovirus classified into the family Flaviviridae and subclassified into the genus Flavivirus. The flaviviruses are transmitted by tick or mosquito vectors and include several clinically significant viruses that cause human infection. Other notable viruses among this family are those known to cause Yellow fever, Japanese encephalitis, West Nile, Dengue, and Zika.[10]

POW virus is a single-stranded RNA virus, and genomic sequencing has identified two distinct lineages or genotypes.[2][11] Though distinguishing these lineages may have epidemiologic importance, cross-neutralization and natural history studies have demonstrated that they are serologically and clinically indistinguishable.[1][12] 

Transmission to humans occurs primarily through the bite of an infected tick. Three main species of ticks have been identified as vectors for the transmission of the POW virus, but Ixodes scapularis (deer tick) is the primary vector.[9][2] Ixodes scapularis also serves as a vector for other common pathogens that cause human infection, including Borrelia burgdorferi, Babesia microti, and Anaplasma phagocytophilum. Ixodes cookei (groundhog tick) and Ixodes marxi (squirrel tick) can also transmit the POW virus but rarely bite humans.[8]

The primary ecologic reservoir for the POW virus is rodents and small mammals. It has been most commonly isolated in mice, groundhogs, voles, and squirrels. However, larger animals such as skunks, foxes, deer, and horses likely play a role in transmission as well.[13][14] 

Once infected, animals develop high viremia and onward transmission to ticks that feed on these infected hosts. Ticks then become vectors for the POW virus, enabling subsequent transmission of the virus to humans or other animals. Infection in humans is not thought to result in high enough viremia levels to result in onward transmission, and thus humans are considered dead-end hosts.[4]

Epidemiology

Although POW virus infection is rare compared to other flavivirus infections, globally, cases have been steadily on the rise in endemic areas. Human infections have been primarily identified in Canada, Russia, and the United States. Within the US, most cases have occurred in New England and the Great Lakes regions, with the highest number of cases reported annually in Minnesota, Wisconsin, Massachusetts, and New York.[15][16] In Canada, cases have been documented in British Columbia, Alberta, and the Maritime provinces. However, the majority have occurred in Eastern Canada, with Ontario and Quebec leading in overall case numbers.[13] Russia has also reported cases, which have predominated in the far eastern province of Primorsky Krai, though seropositive rodents have been identified in other regions, including Siberia.[3] In each region, case incidence peaks between April to November, coinciding with seasonal tick activity, although infections have been reported year-round when milder conditions predominate. 

Seroprevalence studies support a much wider POW distribution across Europe and North America than previously identified by clinical case reports. In Canada and the United States, serologic surveys have shown POW from coast to coast, even extending into parts of northern Mexico.[17] However, cross-reactivity due to the homology of POW virus antigens and those expressed by other flaviviruses may confound some of these studies.[18] 

Few contemporary epidemiologic studies have examined the seroprevalence of POW in endemic areas, but older studies suggest prevalence rates range between 1% to 6%.[19][20] Although it remains unclear if POW virus immunoglobulins wane seasonally or can remain positive lifelong after infection. Comparing seroprevalence data with the low yearly incidence of clinical cases in endemic regions underscores the hypothesis that most infections are mild or sub-clinical and result in neuroinvasive disease.

Over the past decade, there have been several outbreaks of the POW virus. In 2001, a cluster of neuroinvasive cases occurred in Maine and Vermont after years of inactivity, and similar outbreaks have occurred across New England and the midwestern United States.[6][21][22] Between 2010 and 2019, the CDC reported 347 cases of POW virus infection in the United States, of which 166 were neuro-invasive.[23] In 2019 the CDC reported its highest yearly case count of neuroinvasive disease to date with a total of 39 cases, representing a 5-fold increase from 2015.[23] Though it is evident cases are rising, it remains unclear what ecologic or epidemiologic factors may be driving the resurgence of the POW virus.

Pathophysiology

The initial stages of the POW virus disease result from viremia that develops in the setting of an infected tick bite. Animal models have shown that infection can occur in as short as 15 minutes after tick attachment.[24][6] Human studies have validated these observations and have established that infection can occur within three hours of tick attachment.[9] This contrasts the much longer attachment times needed to transmit other common tick-borne infections like Babesia microti, Anaplasma phagocytophilum, and Borrelia burgdorferi. After primary infection occurs, patients can develop non-specific flu-like symptoms that are typically self-limited. Subsequently, days to weeks later, a subset of patients will develop neurologic manifestations that most commonly present as encephalitis or meningoencephalitis.[4][13] The risk factors and molecular mechanisms underlying the progression from mild symptoms to neuroinvasion remain unclear.

History and Physical

The most common clinical presentation of POW virus infection is encephalitis or meningoencephalitis though seroprevalence studies suggest that most infections are sub-clinical. The incubation period ranges from 1 to 5 weeks and can result in a non-specific prodromal illness.[7] This is typified by fever, myalgias, malaise, weakness, headache, and sore throat. Symptoms can also include nausea, vomiting, or a morbilliform rash. The prodromal phase can last 1 to 3 days and always precedes neurologic symptoms.[1] If neurologic manifestations develop, they occur weeks to months after the initial prodromal illness. It remains unknown what percentage of cases will progress to develop neuroinvasive disease or what risk factors might predict worse outcomes among those with neurologic symptoms.

In those who present with severe disease that includes CNS symptoms, it is common to see prolonged fever, confusion, decreased level of consciousness, and seizures. Ocular symptoms can also be seen, such as ophthalmoplegia and nystagmus. Spastic and flaccid paralysis have also been associated with human POW virus infection, but these features are less frequent.[6][14] Although many of these symptoms are common, none are specific to the POW virus, and thus they cannot be used to distinguish it clinically from the syndromes caused by other arboviruses such as West Nile, Eastern Equine, La Crosse, or Saint Louis encephalitis virus.

Evaluation

The evaluation of a patient with suspected POW virus infection should focus on the presence or absence of neurologic symptoms. Those who present with non-specific flu-like symptoms are unlikely to benefit from disease-specific testing. However, in patients with geographic exposure presenting with encephalitis or meningoencephalitis, POW virus testing should be considered. Those with a high clinical suspicion for infection, brain imaging, serology, and lumbar puncture are key aspects of the diagnostic approach. Cerebrospinal fluid (CSF) analysis typically shows a lymphocytic pleocytosis, elevated protein, and normal glucose, though CSF findings can also be unremarkable. Other general laboratory findings may be seen in the peripheral blood, including thrombocytopenia, lymphopenia, and elevated inflammatory markers.  

A confirmatory diagnosis can be made by several methods, direct virus amplification (PCR), detection of IgM antibodies in serum by enzyme immunoassay (EIA), or detection of IgM antibodies in the CSF by EIA are all acceptable.[9][14] However, positive serum IgM tests should be confirmed by a plaque neutralization assay to improve their specificity.[9][4] Serologic tests on the CSF remain the gold standard for confirming neuroinvasive disease through the role of PCR, and metagenomic sequencing may expand in the future.[25] 

Given the overlapping geographic distribution of the POW virus with other arthropod diseases, it is also critical to assess patients for co-infection. Concurrent infections can lead to increased morbidity and mortality when not identified and are often treatable. Observational studies have shown that in those with confirmed POW virus encephalitis, a co-infection with Anaplasma phagocytophilum or Borrelia burgdorferi can be found in 10% to 30% of patients.[26][1]

Treatment / Management

Currently, there is no approved chemoprophylaxis, vaccine, or disease-specific treatment for POW virus infection. Management of patients is supportive and should involve the expertise of an infectious disease specialist. General supportive treatment with intravenous fluids, antipyretics, and critical care, as required, have been effective, but the overall case mortality remains high. Several case reports have proposed the potential use of high-dose corticosteroids or intravenous immunoglobulin (IVIG).[27][25] However, there are no clinical studies supporting improved clinical outcomes with either agent, and caution should be used if considering their use. Data on specific antivirals with activity against POW is also scant, and there are currently no antiviral agents with known efficacy against the POW virus.

Differential Diagnosis

The differential for POW virus infection is broad and will vary depending on a patient’s geographic exposures, host immune status, and other epidemiologic risk factors. However, the differential should encompass the common causes of viral and tick-borne encephalitis.

  • West Nile virus (WNV)
  • Herpes simplex virus (HSV-1 and HSV-2)
  • Varicella-zoster virus (VZV)
  • Cytomegalovirus (CMV)
  • Epstein-Barr virus (EBV)
  • Human Herpesvirus 6 (HHV-6)
  • Neuroborreliosis (Lyme)
  • Anaplasmosis
  • Ehrlichiosis
  • Tick-borne relapsing fever
  • Saint Louis encephalitis virus (SLEV) 
  • Eastern Equine Virus
  • Tick-borne encephalitis virus (TBEV)
  • Adenovirus
  • Influenza A
  • Enterovirus
  • La Crosse virus
  • Dengue
  • Murray Valley encephalitis
  • Japanese encephalitis
  • Bacterial meningitis
  • HIV
  • Neurosyphilis
  • Rabies

Prognosis

The prognosis in most patients infected with the POW virus, who have asymptomatic or mildly symptomatic disease, is thought to be excellent, and asymptomatic infection often goes completely unrecognized. However, a subset of patients progress and will go on to develop neuroinvasive disease, which typically presents as encephalitis or meningoencephalitis. Among these neuroinvasive cases, the mortality rate is high and estimated at 10% to 15%.[6][7]

Complications

In patients who develop severe infections involving the CNS, most of the expected complications result in neurologic disability. In those who develop the neuroinvasive disease but survive, about 50% will have some form of long-lasting neurologic disability.[6]

Retrospective studies have highlighted a wide spectrum of deficits, but the most common include persistent headaches, memory impairment, ataxia, tremor, weakness, encephalopathy, hemiplegia, or persistent ophthalmoplegia.[1][28]

Deterrence and Patient Education

Given the paucity of treatment options, tick education and prevention are central to avoiding infection. Specifically, counseling patients who live in or visit highly endemic areas is recommended for both primary and secondary prevention. Patients should be advised to be mindful of ticks when walking in wooded, grassy, or leaf-littered areas, even within the confines of their own property. This is especially important during the spring, summer, and fall when ticks are most active.

Also, when working or recreating outdoors, patients should be instructed to don light-colored clothing that covers their arms and legs to both prevent exposure and help more easily identify potential ticks. Tucking clothing into socks and pants can also help reduce the likelihood of ticks accessing exposed skin. Chemical repellents such as permethrin or DEET can also be applied to clothing to deter ticks. Once indoors, tick checks should be diligently performed to identify any potential exposures and are best done with the help of a second individual. Prompt tick removal is recommended, but given the short attachment time needed for transmission of the POW virus, this may not be a reliable prevention method.

Enhancing Healthcare Team Outcomes

An interprofessional team approach is essential in the management of POW virus encephalitis and meningoencephalitis. The clinical care team should involve infectious disease, neurology, and critical care clinicians if needed. Patients may also require physical and occupational therapists' expertise to help improve any short or long-term neurologic sequelae that develop. In most US states, Powassan virus infection is a reportable disease, and regional public health authorities should be notified of potential and confirmed cases as active surveillance. Prompt reporting can help identify and mitigate community outbreaks.

References


[1]

Kemenesi G, Bányai K. Tick-Borne Flaviviruses, with a Focus on Powassan Virus. Clinical microbiology reviews. 2019 Jan:32(1):. doi: 10.1128/CMR.00106-17. Epub 2018 Dec 12     [PubMed PMID: 30541872]


[2]

Rochlin I, Toledo A. Emerging tick-borne pathogens of public health importance: a mini-review. Journal of medical microbiology. 2020 Jun:69(6):781-791. doi: 10.1099/jmm.0.001206. Epub 2020 Jun 1     [PubMed PMID: 32478654]


[3]

Leonova GN, Kondratov IG, Ternovoi VA, Romanova EV, Protopopova EV, Chausov EV, Pavlenko EV, Ryabchikova EI, Belikov SI, Loktev VB. Characterization of Powassan viruses from Far Eastern Russia. Archives of virology. 2009:154(5):811-20. doi: 10.1007/s00705-009-0376-y. Epub 2009 Apr 11     [PubMed PMID: 19363586]

Level 3 (low-level) evidence

[4]

Hermance ME, Thangamani S. Powassan Virus: An Emerging Arbovirus of Public Health Concern in North America. Vector borne and zoonotic diseases (Larchmont, N.Y.). 2017 Jul:17(7):453-462. doi: 10.1089/vbz.2017.2110. Epub 2017 May 12     [PubMed PMID: 28498740]


[5]

McLEAN DM, DONOHUE WL. Powassan virus: isolation of virus from a fatal case of encephalitis. Canadian Medical Association journal. 1959 May 1:80(9):708-11     [PubMed PMID: 13652010]

Level 3 (low-level) evidence

[6]

Piantadosi A, Rubin DB, McQuillen DP, Hsu L, Lederer PA, Ashbaugh CD, Duffalo C, Duncan R, Thon J, Bhattacharyya S, Basgoz N, Feske SK, Lyons JL. Emerging Cases of Powassan Virus Encephalitis in New England: Clinical Presentation, Imaging, and Review of the Literature. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 Mar 15:62(6):707-713. doi: 10.1093/cid/civ1005. Epub 2015 Dec 13     [PubMed PMID: 26668338]

Level 3 (low-level) evidence

[7]

Khan M, Beckham JD, Piquet AL, Tyler KL, Pastula DM. An Overview of Powassan Virus Disease. The Neurohospitalist. 2019 Oct:9(4):181-182. doi: 10.1177/1941874419844888. Epub 2019 Apr 21     [PubMed PMID: 31534605]

Level 3 (low-level) evidence

[8]

Campbell O, Krause PJ. The emergence of human Powassan virus infection in North America. Ticks and tick-borne diseases. 2020 Nov:11(6):101540. doi: 10.1016/j.ttbdis.2020.101540. Epub 2020 Aug 7     [PubMed PMID: 32993949]


[9]

Madison-Antenucci S, Kramer LD, Gebhardt LL, Kauffman E. Emerging Tick-Borne Diseases. Clinical microbiology reviews. 2020 Mar 18:33(2):. doi: 10.1128/CMR.00083-18. Epub 2020 Jan 2     [PubMed PMID: 31896541]


[10]

Holbrook MR. Historical Perspectives on Flavivirus Research. Viruses. 2017 Apr 30:9(5):. doi: 10.3390/v9050097. Epub 2017 Apr 30     [PubMed PMID: 28468299]

Level 3 (low-level) evidence

[11]

Beasley DW, Suderman MT, Holbrook MR, Barrett AD. Nucleotide sequencing and serological evidence that the recently recognized deer tick virus is a genotype of Powassan virus. Virus research. 2001 Nov 5:79(1-2):81-9     [PubMed PMID: 11551648]

Level 3 (low-level) evidence

[12]

Ei Khoury MY, Camargo JF, Wormser GP. Changing epidemiology of Powassan encephalitis in North America suggests the emergence of the deer tick virus subtype. Expert review of anti-infective therapy. 2013 Oct:11(10):983-5. doi: 10.1586/14787210.2013.837805. Epub     [PubMed PMID: 24124795]

Level 3 (low-level) evidence

[13]

Ebel GD. Update on Powassan virus: emergence of a North American tick-borne flavivirus. Annual review of entomology. 2010:55():95-110. doi: 10.1146/annurev-ento-112408-085446. Epub     [PubMed PMID: 19961325]

Level 3 (low-level) evidence

[14]

Fatmi SS, Zehra R, Carpenter DO. Powassan Virus-A New Reemerging Tick-Borne Disease. Frontiers in public health. 2017:5():342. doi: 10.3389/fpubh.2017.00342. Epub 2017 Dec 12     [PubMed PMID: 29312918]


[15]

Krow-Lucal ER, Lindsey NP, Fischer M, Hills SL. Powassan Virus Disease in the United States, 2006-2016. Vector borne and zoonotic diseases (Larchmont, N.Y.). 2018 Jun:18(6):286-290. doi: 10.1089/vbz.2017.2239. Epub 2018 Mar 13     [PubMed PMID: 29652642]


[16]

Anderson JF, Armstrong PM. Prevalence and genetic characterization of Powassan virus strains infecting Ixodes scapularis in Connecticut. The American journal of tropical medicine and hygiene. 2012 Oct:87(4):754-9. doi: 10.4269/ajtmh.2012.12-0294. Epub 2012 Aug 13     [PubMed PMID: 22890037]

Level 3 (low-level) evidence

[17]

Pesko KN, Torres-Perez F, Hjelle BL, Ebel GD. Molecular epidemiology of Powassan virus in North America. The Journal of general virology. 2010 Nov:91(Pt 11):2698-705. doi: 10.1099/vir.0.024232-0. Epub 2010 Jul 14     [PubMed PMID: 20631087]

Level 3 (low-level) evidence

[18]

Thomm AM, Schotthoefer AM, Dupuis AP 2nd, Kramer LD, Frost HM, Fritsche TR, Harrington YA, Knox KK, Kehl SC. Development and Validation of a Serologic Test Panel for Detection of Powassan Virus Infection in U.S. Patients Residing in Regions Where Lyme Disease Is Endemic. mSphere. 2018 Jan-Feb:3(1):. doi: 10.1128/mSphere.00467-17. Epub 2018 Jan 10     [PubMed PMID: 29359181]

Level 1 (high-level) evidence

[19]

Dupuis AP 2nd, Peters RJ, Prusinski MA, Falco RC, Ostfeld RS, Kramer LD. Isolation of deer tick virus (Powassan virus, lineage II) from Ixodes scapularis and detection of antibody in vertebrate hosts sampled in the Hudson Valley, New York State. Parasites & vectors. 2013 Jul 15:6():185. doi: 10.1186/1756-3305-6-185. Epub 2013 Jul 15     [PubMed PMID: 24016533]

Level 3 (low-level) evidence

[20]

Corrin T, Greig J, Harding S, Young I, Mascarenhas M, Waddell LA. Powassan virus, a scoping review of the global evidence. Zoonoses and public health. 2018 Sep:65(6):595-624. doi: 10.1111/zph.12485. Epub 2018 Jun 17     [PubMed PMID: 29911344]

Level 2 (mid-level) evidence

[21]

Colman D, Peaslee S. Powassan Virus in a Hunter Returning from a Trip in the Adirondack Park. Wilderness & environmental medicine. 2020 Mar:31(1):87-90. doi: 10.1016/j.wem.2019.09.002. Epub 2020 Jan 29     [PubMed PMID: 32007325]


[22]

Centers for Disease Control and Prevention (CDC). Outbreak of Powassan encephalitis--Maine and Vermont, 1999-2001. MMWR. Morbidity and mortality weekly report. 2001 Sep 7:50(35):761-4     [PubMed PMID: 11787585]

Level 3 (low-level) evidence

[23]

Anonymous A. Powassan Virus: Centers for Disease Control and Prevention. Journal of special operations medicine : a peer reviewed journal for SOF medical professionals. 2019 Winter:19(4):108. doi: 10.55460/4GS0-FVTC. Epub     [PubMed PMID: 31910483]


[24]

Ebel GD, Kramer LD. Short report: duration of tick attachment required for transmission of powassan virus by deer ticks. The American journal of tropical medicine and hygiene. 2004 Sep:71(3):268-71     [PubMed PMID: 15381804]

Level 3 (low-level) evidence

[25]

Piantadosi A, Kanjilal S, Ganesh V, Khanna A, Hyle EP, Rosand J, Bold T, Metsky HC, Lemieux J, Leone MJ, Freimark L, Matranga CB, Adams G, McGrath G, Zamirpour S, Telford S 3rd, Rosenberg E, Cho T, Frosch MP, Goldberg MB, Mukerji SS, Sabeti PC. Rapid Detection of Powassan Virus in a Patient With Encephalitis by Metagenomic Sequencing. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018 Feb 10:66(5):789-792. doi: 10.1093/cid/cix792. Epub     [PubMed PMID: 29020227]


[26]

Frost HM, Schotthoefer AM, Thomm AM, Dupuis AP 2nd, Kehl SC, Kramer LD, Fritsche TR, Harrington YA, Knox KK. Serologic Evidence of Powassan Virus Infection in Patients with Suspected Lyme Disease(1). Emerging infectious diseases. 2017 Aug:23(8):1384-1388. doi: 10.3201/eid2308.161971. Epub     [PubMed PMID: 28726610]


[27]

Dumic I, Madrid C, Vitorovic D. Unusual cause at an unusual time-Powassan virus rhombencephalitis. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2021 Feb:103():88-90. doi: 10.1016/j.ijid.2020.11.159. Epub 2020 Nov 20     [PubMed PMID: 33227515]


[28]

Lessell S, Collins TE. Ophthalmoplegia in Powassan encephalitis. Neurology. 2003 May 27:60(10):1726-7     [PubMed PMID: 12771287]

Level 3 (low-level) evidence